Published • loading... • Updated
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate ...
The study will continue to overall survival after the combination failed to beat Keytruda alone on progression-free survival, BioNTech said.
- On Tuesday, BioNTech reported its experimental mRNA cancer immunotherapy BNT113 failed to meet the first main goal of a Phase 3 trial in patients with head and neck cancer, missing the progression-free survival endpoint.
- The trial tested BNT113 combined with Keytruda against Keytruda alone as a first-line treatment for advanced HNSCC patients with the HPV16 virus.
- Chief Medical Officer Özlem Türeci said early results "support continued evaluation" and show the drug is "engaging its intended therapeutic mechanism," despite missing the primary endpoint.
- US-Listed shares of BioNTech fell nearly 6% on Tuesday following the announcement, though an independent data monitoring committee recommended the study continue to evaluate overall survival.
- Leerink Partners analyst Daina Graybosch noted evidence supporting BNT113 activity was "sparse" when the Phase 3 study launched, as BioNTech pivots resources from infectious disease back to oncology.
Insights by Ground AI
17 Articles
17 Articles
BioNTech’s mRNA Cancer Vaccine Falls Short of Goal in Trial
A messenger ribonucleic acid (mRNA) vaccine against cancer failed to meet a primary goal of a late-stage clinical trial, the shot’s manufacturer said on Oct. 13. The experimental vaccine, known as BNT113, fell short of its primary endpoint of survival without progression of cancer, German-based BioNTech said in a statement. The phase 2/phase 3 clinical trial grouped patients into two groups. One received BNT113 and pembrolizumab, a cancer immun…
·New York, United States
Read Full Article
BioNTech Says Cancer Treatment Didn't Help in Early Analysis
·New York, United States
Read Full Article
BioNTech's mRNA cancer therapy misses first goal in head and neck trial
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left0Leaning Right3Center8Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
C 73%
R 27%
Factuality
To view factuality data please Upgrade to Premium
